Cagri-Sema Blend: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 10 sources cited
Overview
The CagriSema blend combines cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist) in a single formulation, targeting two anatomically and mechanistically distinct satiety pathways for unprecedented weight loss efficacy. This dual-mechanism approach — brainstem amylin signaling plus hypothalamic GLP-1 signaling — produced a mean 20.4% body weight reduction at 68 weeks in the Phase III REDEFINE 1 trial, compared with 3.0% on placebo.
Mechanism of Action
CagriSema exploits the complementary neurobiology of two independent satiety systems that evolved to regulate energy balance through different brain regions: **Semaglutide (GLP-1 pathway):** Activates GLP-1 receptors in the hypothalamic arcuate nucleus and paraventricular nucleus, reducing hunger drive, food reward signaling, and hedonic eating. It also acts in the nucleus tractus solitarius to slow gastric emptying and enhances pancreatic insulin secretion via the incretin effect. The hypothalamic signaling reduces the 'wanting' component of appetite. **Cagrilintide (amylin pathway):** Activates amylin receptors in the area postrema and brainstem, producing meal-related satiety signaling, further slowing gastric emptying, and suppressing glucagon. The brainstem signaling reduces the 'eating' component — promoting earlier satiation during meals. **Synergistic interaction:** Because these two pathways converge on appetite suppression from different anatomical inputs, the combination overcomes the efficacy ceiling of either agent alone. Why the combination works better is not fully established; what trials show is more weight loss with the combination than with either drug alone. The result is deeper and more sustained appetite suppression with additive metabolic benefits on glucose homeostasis (GLP-1 enhances insulin secretion while amylin suppresses glucagon).
Cagri-Sema Blend Benefits: What the Research Shows
- Phase III REDEFINE 1 trial (2025, NEJM, n=3,417): CagriSema achieved 20.4% mean body weight reduction at 68 weeks vs. 3.0% with placebo.
- Across randomized trials, CagriSema participants were about twice as likely as those on semaglutide 2.4 mg alone to lose ≥20% of body weight (pooled risk ratio 2.10), with 6.9 percentage points more weight loss on average.
- Glycemic control: in a 32-week Phase II trial in type 2 diabetes, HbA1c fell 2.2 percentage points with CagriSema, versus 1.8 with semaglutide (difference not significant) and 0.9 with cagrilintide; the Phase III REIMAGINE 2 trial found a small but significant advantage over semaglutide 2.4 mg (1.91 vs. 1.75).
- In the 32-week Phase II trial in type 2 diabetes, weight loss with the combination (15.6%) exceeded semaglutide alone (5.1%) and cagrilintide alone (8.1%), consistent with roughly additive effects of the two pathways.
- CagriSema is not FDA-approved. As of an FDA statement current in October 2026, cagrilintide was not a component of any approved drug and could not be used in compounding.
- Cardiovascular outcome data is pending: the REDEFINE 3 trial has randomized 7,076 adults with cardiovascular disease to CagriSema or placebo and has not yet reported.
Cagri-Sema Blend Dosage
- Research blend typically supplied as 5 mg cagrilintide / 5 mg semaglutide per vial (10 mg total). Reconstitute with bacteriostatic water per vial instructions.
- Dose escalation is mandatory: Start with low doses of both components and escalate over 8–16 weeks. Rushing escalation dramatically increases nausea and vomiting.
- Example escalation: Week 1–4: 0.25 mg each weekly → Weeks 5–8: 0.5 mg each → Weeks 9–12: 1 mg each → Weeks 13–16: target maintenance dose of 2.4 mg each.
- Inject once weekly subcutaneously in abdomen, thigh, or upper arm. Rotate sites weekly.
- Take on the same day each week for consistent levels.
- Nausea management: slow escalation, ginger root extract, small frequent meals. Ondansetron (Zofran) 4 mg as needed for severe nausea.
- Monitor: body weight weekly, fasting glucose monthly, lipid panel and HbA1c quarterly. Report severe abdominal pain (pancreatitis screen).
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Cagri-Sema Blend Side Effects & Safety
Known Side Effects
- Nausea — the most common side effect, affecting 30–45% of patients. Most prevalent during dose escalation and diminishing over 8–12 weeks. Proper slow escalation is the primary mitigation strategy.
- Vomiting — reported in 15–20% of patients, concentrated during escalation phase.
- Diarrhea and constipation — GI motility effects from dual-pathway activation on gastric emptying.
- Decreased appetite — the intended therapeutic effect, but can be excessive in some patients. Ensure adequate protein and micronutrient intake despite reduced hunger.
- Injection site reactions — mild and self-resolving in most cases.
- Potential pancreatitis risk — low incidence in clinical trials but requires vigilance. Report severe, persistent abdominal pain immediately.
- Gallbladder events — rapid weight loss increases gallstone risk, a class effect of all potent weight loss therapies.
Safety Profile
The CagriSema blend's safety profile reflects the combined profiles of both well-studied components. Semaglutide has extensive Phase III and post-marketing safety data from millions of patients worldwide. Cagrilintide has Phase II and III data with thousands of patients. The pharmaceutical combination (CagriSema, a fixed-dose product given from a dual-chamber pen) has been studied in Phase III with the safety profile consistent with expectations — predominantly GI side effects. Vials that mix the two peptides have not been studied. CagriSema has no approved label yet. Going by the semaglutide label, it should not be used with a personal/family history of medullary thyroid carcinoma or MEN2 syndrome; semaglutide is also not recommended in severe gastroparesis, should be stopped if pancreatitis is suspected, and should be discontinued when pregnancy is recognized. Concurrent use with sulfonylureas or insulin requires dose adjustment due to additive hypoglycemic risk. Patients should be counseled about the importance of adequate nutrition despite reduced appetite — protein intake of at least 0.8 g/kg/day should be maintained to preserve lean mass during rapid weight loss.
What to Expect
Weeks 1–4 (early escalation): Appetite reduction begins even at starting doses. Nausea is most common during this period — manage with slow escalation and supportive measures. Weight loss of 2–5 lbs is typical even at low doses. Weeks 5–12 (dose escalation): As doses increase, appetite suppression deepens significantly. Many users report dramatic changes in their relationship with food — reduced cravings, smaller portions, less interest in calorie-dense foods. Weight loss accelerates to 1.5–2.5 lbs per week. Weeks 13–26 (maintenance dosing): At target dose, appetite suppression is strong and consistent. Weight loss continues at a steady pace. GI side effects have typically resolved. Metabolic markers (glucose, HbA1c, lipids, blood pressure) improve significantly. Weeks 27–68+: Continued weight loss with gradual deceleration as a new equilibrium is approached. Mean weight loss of 20.4% at 68 weeks in the REDEFINE 1 trial. Some patients achieve 25–35% total body weight loss. Body composition improvements (reduced visceral fat, improved waist-hip ratio) are dramatic. Long-term maintenance dosing is likely required to sustain weight loss.
Common Stacks
AOD-9604
AOD-9604 provides peripheral, direct lipolysis without central appetite effects, adding a third mechanism of action (direct fat metabolism) to CagriSema's dual central appetite suppression.
Ipamorelin
Ipamorelin-driven GH release supports lean mass preservation during the significant weight loss produced by CagriSema, helping ensure weight loss is predominantly fat mass.
BPC-157
BPC-157's GI protective properties may help mitigate the gastrointestinal side effects (nausea, GI irritation) associated with CagriSema, while providing additional metabolic and gut health benefits.
Storage & Handling
Store lyophilized powder refrigerated at 36–46°F (2–8°C). After reconstitution with bacteriostatic water, refrigerate and use within 4 weeks. Do not freeze reconstituted solution. Since this is a blend, ensure thorough but gentle mixing after reconstitution. Unreconstituted vials can be stored frozen at -4°F (-20°C) for extended shelf life.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025.
- Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025.
- Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026.
- Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023.
- Rasool ZK, Shah R, Batool AEZ, et al. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis. Front Endocrinol (Lausanne). 2026.
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021.
- Cavender MA, Jastreboff AM, Cheng AYY, et al. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Am Heart J. 2026.
- Gulisano W, Ter-Borch G, Brown P, et al. Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes. J Diabetes Sci Technol. 2026.
- Wegovy (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed. 2026.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026.
Related Peptides
Track Cagri-Sema Blend in Your Protocol
Log your Cagri-Sema Blend doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free